Late last week, the psychedelics industry received its latest blow when the FDA shot down Lykos Therapeutics’ application for MDMA-assisted therapy for treating PTSD. Many in the psychedelics industry had hailed Lykos Therapeutics’ treatment as the pioneer for regulatory clearance. However, the FDA sent the pharma company back to the drawing board for more testing, […]
Reason for Hope
The psychedelic industry learned important lessons when a Food and Drug Administration advisory committee voted to reject a landmark MDMA-based therapy designed to treat PTSD. The rejection shook investors and demonstrates that FDA approval for novel psychedelic drugs is further away than previously thought, but industry insiders remain confident in the industry’s long-term success. The […]